Brand vs Generic: The Billion-Dollar Gap

Generic drugs are bioequivalent to their brand-name counterparts but cost a fraction of the price. Every brand-name prescription where a generic exists represents potential waste — and the numbers add up fast.

The Overall Picture

In 2023, Medicare Part D spent $185.46B on brand-name drugs and $39.45B on generics. The overall brand rate across all prescribers is approximately 13.4%.

That gap is not just a rounding error. Brand-name drugs account for roughly 10% of all prescriptions dispensed under Part D but consume more than 70% of total drug spending. The per-claim cost of a brand drug averages six to ten times that of a generic equivalent, a spread that has widened steadily over the past decade as brand manufacturers raise list prices faster than inflation.

Why Generics Cost Less

When a pharmaceutical company develops a new drug, it typically holds patent protection for 20 years from the date of filing. During that window, no competitor can manufacture the same molecule, giving the originator company a legal monopoly and the pricing power that comes with it. The company must recoup research and development costs, clinical trial expenses, and FDA review fees — costs that can exceed $1 billion per approved molecule.

Once the patent expires, generic manufacturers can file an Abbreviated New Drug Application (ANDA) with the FDA. The ANDA process is faster and cheaper because the generic maker does not need to repeat the full suite of clinical trials. They must demonstrate bioequivalence — that the generic delivers the same active ingredient, at the same rate and extent, to the bloodstream. The FDA holds generics to the same manufacturing quality standards as brands.

Competition does the rest. Once two or three generic manufacturers enter the market, prices typically fall 70-80% below the original brand price. With six or more competitors, prices can drop 95% or more. This is why a drug like atorvastatin (generic Lipitor) costs a few dollars a month while certain newer brand-name statins cost hundreds.

The Scale of the Problem

Medicare Part D covers more than 50 million beneficiaries and processes over 4.5 billion prescriptions per year. Even small shifts in the brand-to-generic mix produce enormous dollar swings. According to the Association for Accessible Medicines, generic and biosimilar drugs saved the U.S. health system an estimated $407 billion in 2023 alone.

But the savings already captured only tell half the story. A significant volume of brand-name prescriptions are written for drugs that have perfectly suitable generic alternatives. CMS data shows that if every prescriber in the country matched the brand rate of the most efficient quartile in their own specialty, Part D spending could fall by an estimated $0 per year — without changing a single clinical outcome.

Those unrealized savings are not evenly distributed. A relatively small number of high-volume prescribers with elevated brand rates account for a disproportionate share of the gap. Identifying those outliers is one of the goals of OpenPrescriber's brand-vs-generic analysis.

Which Specialties Prescribe the Most Brands

Not all brand prescribing is wasteful. Oncologists rely heavily on patented biologics and targeted therapies that have no generic equivalent. Rheumatologists prescribe brand-name biologics for autoimmune conditions where biosimilar uptake is still growing. In those specialties, high brand rates reflect the available formulary, not prescriber preference.

Other specialties are harder to justify. When a primary care physician or internist has a brand rate well above their peers, it usually signals one of three things: heavy pharmaceutical marketing influence, patient request driven by direct-to-consumer advertising, or simple clinical inertia — continuing to prescribe a brand they learned about in training even after generics became available.

The table above ranks specialties by their average brand-name prescribing rate among providers with at least 50 Part D claims. Look for specialties where generic alternatives are widely available — those are the areas with the greatest room for improvement.

Geographic Variation

Brand prescribing rates vary dramatically by state. Southern states tend to report higher brand rates than the national average, while states in the upper Midwest and Pacific Northwest tend to be lower. The spread between the highest-brand and lowest-brand states can exceed 15 percentage points.

These geographic differences persist even after controlling for specialty mix and patient demographics. Some of the variation is explained by state-level formulary policies, Medicaid–Medicare dual-eligible populations, and the density of academic medical centers (which tend to adopt generics faster). But a significant portion traces back to regional prescribing culture and the intensity of pharmaceutical sales activity in a given market.

You can explore provider-level brand rates by state in the Brand vs Generic Explorer and drill down to individual providers in the provider directory.

The Pharmaceutical Marketing Machine

The pharmaceutical industry spends roughly $20 billion per year on marketing to healthcare professionals in the United States. That figure includes direct sales-rep visits (known as "detailing"), free drug samples, sponsored continuing-education events, speaker fees, and consulting arrangements. It does not include direct-to-consumer advertising, which adds another $6-8 billion annually.

Free samples deserve special attention. They are the single most effective tool for establishing brand loyalty. A physician who hands a patient free samples of a brand-name drug during an office visit has effectively locked that patient into the brand — once the samples run out, the prescription is already written and refilling with the same drug is the path of least resistance. Studies have consistently shown that physicians who receive more samples prescribe more brand-name drugs, even when generics are available and clinically equivalent.

Formulary influence is subtler but equally powerful. Brand manufacturers negotiate rebates with pharmacy benefit managers (PBMs) to secure preferred formulary placement. A brand drug with a large rebate may appear on a lower copay tier than a generic competitor, creating the perverse result that the patient pays less for the brand at the pharmacy counter while the system as a whole pays more. These arrangements obscure the true cost of brand drugs and make it harder for prescribers and patients to make cost-conscious choices.

Pay-for-Delay

Even after a patent expires, brand manufacturers have tools to delay generic entry. The most controversial is the "pay-for-delay" settlement — also called a reverse-payment agreement. In these deals, a brand manufacturer facing a patent challenge from a generic maker pays the generic company to drop its challenge and stay off the market for a specified period.

The Federal Trade Commission has estimated that pay-for-delay agreements cost consumers and taxpayers $3.5 billion per year in higher drug prices. While the Supreme Court ruled in FTC v. Actavis (2013) that these deals can violate antitrust law, they have not disappeared entirely. Manufacturers have shifted to more complex arrangements — authorized generics, licensing deals, and patent thickets — that achieve similar delays without the explicit cash payments that attract regulatory scrutiny.

Other tactics include filing additional patents on minor formulation changes (so-called "evergreening"), obtaining pediatric exclusivity extensions, and using Risk Evaluation and Mitigation Strategies (REMS) requirements to restrict generic access to drug samples needed for bioequivalence testing. The cumulative effect is that many drugs remain brand-only for years beyond their original patent expiration.

The Patient Impact

For Medicare beneficiaries, the brand-generic gap is not an abstract policy question — it directly affects what they pay at the pharmacy. Under the standard Part D benefit structure, patients pay a percentage of a drug's cost as coinsurance. For a brand-name drug on a non-preferred tier, that coinsurance can be 25-33%, compared to a flat copay of $3-12 for most generics.

The coverage gap — commonly known as the "donut hole" — amplifies the problem. Once a beneficiary's total drug costs reach a certain threshold (roughly $5,030 in 2024), they enter a phase where they are responsible for a larger share of costs until catastrophic coverage kicks in. Brand-name drugs push patients into the donut hole faster because of their higher per-claim cost, and once there, the financial exposure is greater.

The Inflation Reduction Act of 2022 introduced a $2,000 annual out-of-pocket cap for Part D starting in 2025, which provides meaningful relief. But the cap does not eliminate the incentive to use generics — it simply shifts the excess cost from the patient to Medicare and plan sponsors, making system-wide efficiency even more important.

Beyond dollar amounts, cost-related non-adherence remains a serious clinical concern. Roughly one in four Medicare beneficiaries report skipping doses, splitting pills, or not filling prescriptions because of cost. Switching these patients to generic alternatives could improve adherence and outcomes while reducing their out-of-pocket burden.

What CMS Is Doing

The Inflation Reduction Act (IRA) gave Medicare the authority to negotiate prices directly with drug manufacturers for the first time. Beginning in 2026, CMS will negotiate prices for a set of high-spend Part D drugs, with the number of negotiated drugs expanding each year. The first ten drugs selected for negotiation include several high-cost brand-name medications that account for billions in annual Part D spending.

Separately, the IRA imposed inflation-based rebates on drug manufacturers whose price increases outpace the consumer price index. If a brand manufacturer raises a drug's price faster than inflation, they must pay a rebate back to Medicare — a provision that directly discourages the aggressive list-price increases that have characterized brand drugs for years.

CMS has also expanded its use of star ratings and quality measures that incorporate generic prescribing rates, encouraging Part D plans to steer members toward generic alternatives through formulary design and pharmacist interventions. These measures are imperfect — they do not distinguish between appropriate and inappropriate brand use — but they create a structural incentive for plans to promote generics.

How We Flag This

On OpenPrescriber, brand-name prescribing rate is one of several components in our composite risk scoring methodology. We compare each provider's brand rate to the median for their specialty, then flag outliers who fall significantly above that benchmark.

A high brand rate alone does not mean a provider is doing anything wrong. Some patients genuinely need brand-name medications due to narrow therapeutic index drugs, documented allergies to inactive ingredients in generics, or conditions where only brand-name options exist. That is why we present brand rate as one signal among many — alongside cost per claim, opioid prescribing patterns, and peer comparison — rather than as a standalone judgment.

Each provider's profile page shows their brand rate in context: relative to their specialty median, trended over time where data permits, and broken down by drug class. You can view any provider's detail at the provider directory and see exactly where their prescribing patterns diverge from their peers.

What You Can Do

If you are a Medicare beneficiary, ask your prescriber whether a generic alternative exists for any brand-name drug you are currently taking. Pharmacists are another excellent resource — in many states, pharmacists can automatically substitute a generic unless the prescriber explicitly writes "dispense as written."

If you are a prescriber, review your own brand rate on OpenPrescriber and compare it to your specialty peers. Consider whether each brand-name prescription you write is clinically necessary or whether a generic would serve the patient equally well. Small changes multiplied across a full patient panel add up to meaningful savings — for both the system and your patients.

If you are a policymaker, researcher, or journalist, use the data on our Brand vs Generic Explorer to identify geographic and specialty-level patterns worth investigating. All of the data on OpenPrescriber is derived from publicly available CMS datasets and is free to explore, download, and cite.